Skip to content
Corporate Investor Seed Series A Series B Series C Bridge Est. 2000

Medytox

Developing botulinum toxins, synthetic drugs, supplements & medical devices

📍 Seoul, South Korea

About This Fund

Medytox has developed a botulinum toxin for medical aesthetics & therapeutic applications. The product, Meditoxin, a botulinum toxin type A marketed under trade names Neuronox, INNOTOX & Coretox. These products are used for the treatments of muscle spasticity, foot deformities, Benign essential blepharospasm & globular wrinkles. Also developed Hyaluronic Acid Filler (branded as Neuramis & Potenfill) to the treatment of facial wrinkles and physical recovery. Also developed medical devices for tissue coagulation & injecting applications. The company is also developing the pipeline of biodrugs, medical devices, synthetic drugs & health supplements.

Investment Focus

Sectors
healthcare biotech pharmaceuticals medical devices
Stages
Seed Series A Series B Series C Bridge
Check Size $1M-$15M
Geography
South Korea

What They Look For

Innovative early-stage startups in healthcare with tech potential for TIPS grants; South Korea focus; strong alignment with Medytox Group's pharma/med device expertise

Preparing to pitch Medytox?

CrackTheDeck analyzes your pitch deck before the meeting — structure, narrative, investor fit.

Analyze My Deck →